Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design.

Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. J Am Chem Soc. 2010 Jun 02; 132(21):7242-3.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.